0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Single-cell multiome sequencing clarifies enteric glial diversity and identifies an intraganglionic population poised for neurogenesis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          The enteric nervous system (ENS) consists of glial cells (EGCs) and neurons derived from neural crest precursors. EGCs retain capacity for large-scale neurogenesis in culture, and in vivo lineage tracing has identified neurons derived from glial cells in response to inflammation. We thus hypothesize that EGCs possess a chromatin structure poised for neurogenesis. We use single-cell multiome sequencing to simultaneously assess transcription and chromatin accessibility in EGCs undergoing spontaneous neurogenesis in culture, as well as small intestine myenteric plexus EGCs. Cultured EGCs maintain open chromatin at genomic loci accessible in neurons, and neurogenesis from EGCs involves dynamic chromatin rearrangements with a net decrease in accessible chromatin. A subset of in vivo EGCs, highly enriched within the myenteric ganglia and that persist into adulthood, have a gene expression program and chromatin state consistent with neurogenic potential. These results clarify the mechanisms underlying EGC potential for neuronal fate transition.

          Graphical abstract

          In brief

          By performing comprehensive single-cell transcriptomic and chromatin accessibility profiling of enteric glial cells both in culture and freshly isolated from mouse small intestine, Guyer et al. identify intraganglionic glia as a distinct subpopulation of enteric glial cells that are epigenetically poised for neurogenesis.

          Related collections

          Most cited references59

          • Record: found
          • Abstract: found
          • Article: not found

          Fiji: an open-source platform for biological-image analysis.

          Fiji is a distribution of the popular open-source software ImageJ focused on biological-image analysis. Fiji uses modern software engineering practices to combine powerful software libraries with a broad range of scripting languages to enable rapid prototyping of image-processing algorithms. Fiji facilitates the transformation of new algorithms into ImageJ plugins that can be shared with end users through an integrated update system. We propose Fiji as a platform for productive collaboration between computer science and biology research communities.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Model-based Analysis of ChIP-Seq (MACS)

            Background The determination of the 'cistrome', the genome-wide set of in vivo cis-elements bound by trans-factors [1], is necessary to determine the genes that are directly regulated by those trans-factors. Chromatin immunoprecipitation (ChIP) [2] coupled with genome tiling microarrays (ChIP-chip) [3,4] and sequencing (ChIP-Seq) [5-8] have become popular techniques to identify cistromes. Although early ChIP-Seq efforts were limited by sequencing throughput and cost [2,9], tremendous progress has been achieved in the past year in the development of next generation massively parallel sequencing. Tens of millions of short tags (25-50 bases) can now be simultaneously sequenced at less than 1% the cost of traditional Sanger sequencing methods. Technologies such as Illumina's Solexa or Applied Biosystems' SOLiD™ have made ChIP-Seq a practical and potentially superior alternative to ChIP-chip [5,8]. While providing several advantages over ChIP-chip, such as less starting material, lower cost, and higher peak resolution, ChIP-Seq also poses challenges (or opportunities) in the analysis of data. First, ChIP-Seq tags represent only the ends of the ChIP fragments, instead of precise protein-DNA binding sites. Although tag strand information and the approximate distance to the precise binding site could help improve peak resolution, a good tag to site distance estimate is often unknown to the user. Second, ChIP-Seq data exhibit regional biases along the genome due to sequencing and mapping biases, chromatin structure and genome copy number variations [10]. These biases could be modeled if matching control samples are sequenced deeply enough. However, among the four recently published ChIP-Seq studies [5-8], one did not have a control sample [5] and only one of the three with control samples systematically used them to guide peak finding [8]. That method requires peaks to contain significantly enriched tags in the ChIP sample relative to the control, although a small ChIP peak region often contains too few control tags to robustly estimate the background biases. Here, we present Model-based Analysis of ChIP-Seq data, MACS, which addresses these issues and gives robust and high resolution ChIP-Seq peak predictions. We conducted ChIP-Seq of FoxA1 (hepatocyte nuclear factor 3α) in MCF7 cells for comparison with FoxA1 ChIP-chip [1] and identification of features unique to each platform. When applied to three human ChIP-Seq datasets to identify binding sites of FoxA1 in MCF7 cells, NRSF (neuron-restrictive silencer factor) in Jurkat T cells [8], and CTCF (CCCTC-binding factor) in CD4+ T cells [5] (summarized in Table S1 in Additional data file 1), MACS gives results superior to those produced by other published ChIP-Seq peak finding algorithms [8,11,12]. Results Modeling the shift size of ChIP-Seq tags ChIP-Seq tags represent the ends of fragments in a ChIP-DNA library and are often shifted towards the 3' direction to better represent the precise protein-DNA interaction site. The size of the shift is, however, often unknown to the experimenter. Since ChIP-DNA fragments are equally likely to be sequenced from both ends, the tag density around a true binding site should show a bimodal enrichment pattern, with Watson strand tags enriched upstream of binding and Crick strand tags enriched downstream. MACS takes advantage of this bimodal pattern to empirically model the shifting size to better locate the precise binding sites. Given a sonication size (bandwidth) and a high-confidence fold-enrichment (mfold), MACS slides 2bandwidth windows across the genome to find regions with tags more than mfold enriched relative to a random tag genome distribution. MACS randomly samples 1,000 of these high-quality peaks, separates their Watson and Crick tags, and aligns them by the midpoint between their Watson and Crick tag centers (Figure 1a) if the Watson tag center is to the left of the Crick tag center. The distance between the modes of the Watson and Crick peaks in the alignment is defined as 'd', and MACS shifts all the tags by d/2 toward the 3' ends to the most likely protein-DNA interaction sites. Figure 1 MACS model for FoxA1 ChIP-Seq. (a,b) The 5' ends of strand-separated tags from a random sample of 1,000 model peaks, aligned by the center of their Watson and Crick peaks (a) and by the FKHR motif (b). (c) The tag count in ChIP versus control in 10 kb windows across the genome. Each dot represents a 10 kb window; red dots are windows containing ChIP peaks and black dots are windows containing control peaks used for FDR calculation. (d) Tag density profile in control samples around FoxA1 ChIP-Seq peaks. (e,f) MACS improves the motif occurrence in the identified peak centers (e) and the spatial resolution (f) for FoxA1 ChIP-Seq through tag shifting and λlocal. Peaks are ranked by p-value. The motif occurrence is calculated as the percentage of peaks with the FKHR motif within 50 bp of the peak summit. The spatial resolution is calculated as the average distance from the summit to the nearest FKHR motif. Peaks with no FKHR motif within 150 bp of the peak summit are removed from the spatial resolution calculation. When applied to FoxA1 ChIP-Seq, which was sequenced with 3.9 million uniquely mapped tags, MACS estimates the d to be only 126 bp (Figure 1a; suggesting a tag shift size of 63 bp), despite a sonication size (bandwidth) of around 500 bp and Solexa size-selection of around 200 bp. Since the FKHR motif sequence dictates the precise FoxA1 binding location, the true distribution of d could be estimated by aligning the tags by the FKHR motif (122 bp; Figure 1b), which gives a similar result to the MACS model. When applied to NRSF and CTCF ChIP-Seq, MACS also estimates a reasonable d solely from the tag distribution: for NRSF ChIP-Seq the MACS model estimated d as 96 bp compared to the motif estimate of 70 bp; applied to CTCF ChIP-Seq data the MACS model estimated a d of 76 bp compared to the motif estimate of 62 bp. Peak detection For experiments with a control, MACS linearly scales the total control tag count to be the same as the total ChIP tag count. Sometimes the same tag can be sequenced repeatedly, more times than expected from a random genome-wide tag distribution. Such tags might arise from biases during ChIP-DNA amplification and sequencing library preparation, and are likely to add noise to the final peak calls. Therefore, MACS removes duplicate tags in excess of what is warranted by the sequencing depth (binomial distribution p-value 2). Among the remaining 34.6% ChIP-Seq unique peaks, 1,045 (13.3%) were not tiled or only partially tiled on the arrays due to the array design. Therefore, only 21.4% of ChIP-Seq peaks are indeed specific to the sequencing platform. Furthermore, ChIP-chip targets with higher fold-enrichments are more likely to be reproducibly detected by ChIP-Seq with a higher tag count (Figure 3b). Meanwhile, although the signals of array probes at the ChIP-Seq specific peak regions are below the peak-calling cutoff, they show moderate signal enrichments that are significantly higher than the genomic background (Wilcoxon p-value 2) and ChIP-Seq (MACS; FDR <1%). Shown are the numbers of regions detected by both platforms (that is, having at least 1 bp in common) or unique to each platform. (b) The distributions of ChIP-Seq tag number and ChIP-chip MATscore [13] for FoxA1 binding sites identified by both platforms. (c) MATscore distributions of FoxA1 ChIP-chip at ChIP-Seq/chip overlapping peaks, ChIP-Seq unique peaks, and genome background. For each peak, the mean MATscore for all probes within the 300 bp region centered at the ChIP-Seq peak summit is used. Genome background is based on MATscores of all array probes in the FoxA1 ChIP-chip data. (d) Width distributions of FoxA1 ChIP-Seq/chip overlapping peaks and ChIP-Seq unique peaks at different fold-enrichments (less than 25, 25 to 50, and larger than 50). (e) Spatial resolution for FoxA1 ChIP-chip and ChIP-Seq peaks. The Wilcoxon test was used to calculate the p-values for (d) and (e). (f) Motif occurrence within the central 200 bp regions for FoxA1 ChIP-Seq/chip overlapping peaks and platform unique peaks. Error bars showing standard deviation were calculated from random sampling of 500 peaks ten times for each category. Background motif occurrences are based on 100,000 randomly selected 200 bp regions in the human genome, excluding regions in genome assembly gaps (containing 'N'). Comparing the difference between ChIP-chip and ChIP-Seq peaks, we find that the average peak width from ChIP-chip is twice as large as that from ChIP-Seq. The average distance from peak summit to motif is significantly smaller in ChIP-Seq than ChIP-chip (Figure 3e), demonstrating the superior resolution of ChIP-Seq. Under the same 1% FDR cutoff, the FKHR motif occurrence within the central 200 bp from ChIP-chip or ChIP-Seq specific peaks is comparable with that from the overlapping peaks (Figure 3f). This suggests that most of the platform-specific peaks are genuine binding sites. A comparison between NRSF ChIP-Seq and ChIP-chip (Figure S3 in Additional data file 1) yields similar results, although the overlapping peaks for NRSF are of much better quality than the platform-specific peaks. Discussion ChIP-Seq users are often curious as to whether they have sequenced deep enough to saturate all the binding sites. In principle, sequencing saturation should be dependent on the fold-enrichment, since higher-fold peaks are saturated earlier than lower-fold ones. In addition, due to different cost and throughput considerations, different users might be interested in recovering sites at different fold-enrichment cutoffs. Therefore, MACS produces a saturation table to report, at different fold-enrichments, the proportion of sites that could still be detected when using 90% to 20% of the tags. Such tables produced for FoxA1 (3.9 million tags) and NRSF (2.2 million tags) ChIP-Seq data sets (Figure S4 in Additional data file 1; CTCF does not have a control to robustly estimate fold-enrichment) show that while peaks with over 60-fold enrichment have been saturated, deeper sequencing could still recover more sites less than 40-fold enriched relative to the chromatin input DNA. As sequencing technologies improve their throughput, researchers are gradually increasing their sequencing depth, so this question could be revisited in the future. For now, we leave it up to individual users to make an informed decision on whether to sequence more based on the saturation at different fold-enrichment levels. The d modeled by MACS suggests that some short read sequencers such as Solexa may preferentially sequence shorter fragments in a ChIP-DNA pool. This may contribute to the superior resolution observed in ChIP-Seq data, especially for activating transcription and epigenetic factors in open chromatin. However, for repressive factors targeting relatively compact chromatin, the target regions might be harder to sonicate into the soluble extract. Furthermore, in the resulting ChIP-DNA, the true targets may tend to be longer than the background DNA in open chromatin, making them unfavorable for size-selection and sequencing. This implies that epigenetic markers of closed chromatin may be harder to ChIP, and even harder to ChIP-Seq. To assess this potential bias, examining the histone mark ChIP-Seq results from Mikkelsen et al. [7], we find that while the ChIP-Seq efficiency of the active mark H3K4me3 remains high as pluripotent cells differentiate, that of repressive marks H3K27me3 and H3K9me3 becomes lower with differentiation (Table S2 in Additional data file 1), even though it is likely that there are more targets for these repressive marks as cells differentiate. We caution ChIP-Seq users to adopt measures to compensate for this bias when ChIPing repressive marks, such as more vigorous sonication, size-selecting slightly bigger fragments for library preparation, or sonicating the ChIP-DNA further between decrosslinking and library preparation. MACS calculates the FDR based on the number of peaks from control over ChIP that are called at the same p-value cutoff. This FDR estimate is more robust than calculating the FDR from randomizing tags along the genome. However, we notice that when tag counts from ChIP and controls are not balanced, the sample with more tags often gives more peaks even though MACS normalizes the total tag counts between the two samples (Figure S5 in Additional data file 1). While we await more available ChIP-Seq data with deeper coverage to understand and overcome this bias, we suggest to ChIP-Seq users that if they sequence more ChIP tags than controls, the FDR estimate of their ChIP peaks might be overly optimistic. Conclusion As developments in sequencing technology popularize ChIP-Seq, we propose a novel algorithm, MACS, for its data analysis. MACS offers four important utilities for predicting protein-DNA interaction sites from ChIP-Seq. First, MACS improves the spatial resolution of the predicted sites by empirically modeling the distance d and shifting tags by d/2. Second, MACS uses a dynamic λlocal parameter to capture local biases in the genome and improves the robustness and specificity of the prediction. It is worth noting that in addition to ChIP-Seq, λlocal can potentially be applied to other high throughput sequencing applications, such as copy number variation and digital gene expression, to capture regional biases and estimate robust fold-enrichment. Third, MACS can be applied to ChIP-Seq experiments without controls, and to those with controls with improved performance. Last but not least, MACS is easy to use and provides detailed information for each peak, such as genome coordinates, p-value, FDR, fold_enrichment, and summit (peak center). Materials and methods Dataset ChIP-Seq data for three factors, NRSF, CTCF, and FoxA1, were used in this study. ChIP-chip and ChIP-Seq (2.2 million ChIP and 2.8 million control uniquely mapped reads, simplified as 'tags') data for NRSF in Jurkat T cells were obtained from Gene Expression Omnibus (GSM210637) and Johnson et al. [8], respectively. ChIP-Seq (2.9 million ChIP tags) data for CTCF in CD4+ T cells were derived from Barski et al. [5]. ChIP-chip data for FoxA1 and controls in MCF7 cells were previously published [1], and their corresponding ChIP-Seq data were generated specifically for this study. Around 3 ng FoxA1 ChIP DNA and 3 ng control DNA were used for library preparation, each consisting of an equimolar mixture of DNA from three independent experiments. Libraries were prepared as described in [8] using a PCR preamplification step and size selection for DNA fragments between 150 and 400 bp. FoxA1 ChIP and control DNA were each sequenced with two lanes by the Illumina/Solexa 1G Genome Analyzer, and yielded 3.9 million and 5.2 million uniquely mapped tags, respectively. Software implementation MACS is implemented in Python and freely available with an open source Artistic License at [16]. It runs from the command line and takes the following parameters: -t for treatment file (ChIP tags, this is the ONLY required parameter for MACS) and -c for control file containing mapped tags; --format for input file format in BED or ELAND (output) format (default BED); --name for name of the run (for example, FoxA1, default NA); --gsize for mappable genome size to calculate λBG from tag count (default 2.7G bp, approximately the mappable human genome size); --tsize for tag size (default 25); --bw for bandwidth, which is half of the estimated sonication size (default 300); --pvalue for p-value cutoff to call peaks (default 1e-5); --mfold for high-confidence fold-enrichment to find model peaks for MACS modeling (default 32); --diag for generating the table to evaluate sequence saturation (default off). In addition, the user has the option to shift tags by an arbitrary number (--shiftsize) without the MACS model (--nomodel), to use a global lambda (--nolambda) to call peaks, and to show debugging and warning messages (--verbose). If a user has replicate files for ChIP or control, it is recommended to concatenate all replicates into one input file. The output includes one BED file containing the peak chromosome coordinates, and one xls file containing the genome coordinates, summit, p-value, fold_enrichment and FDR (if control is available) of each peak. For FoxA1 ChIP-Seq in MCF7 cells with 3.9 million and 5.2 million ChIP and control tags, respectively, it takes MACS 15 seconds to model the ChIP-DNA size distribution and less than 3 minutes to detect peaks on a 2 GHz CPU Linux computer with 2 GB of RAM. Figure S6 in Additional data file 1 illustrates the whole process with a flow chart. Abbreviations ChIP, chromatin immunoprecipitation; CTCF, CCCTC-binding factor; FDR, false discovery rate; FoxA1, hepatocyte nuclear factor 3α; MACS, Model-based Analysis of ChIP-Seq data; NRSF, neuron-restrictive silencer factor. Authors' contributions XSL, WL and YZ conceived the project and wrote the paper. YZ, TL and CAM designed the algorithm, performed the research and implemented the software. JE, DSJ, BEB, CN, RMM and MB performed FoxA1 ChIP-Seq experiments and contributed to ideas. All authors read and approved the final manuscript. Additional data files The following additional data are available. Additional data file 1 contains supporting Figures S1-S6, and supporting Tables S1 and S2. Supplementary Material Additional data file 1 Figures S1-S6, and Tables S1 and S2. Click here for file
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Integrative Genomics Viewer

              To the Editor Rapid improvements in sequencing and array-based platforms are resulting in a flood of diverse genome-wide data, including data from exome and whole genome sequencing, epigenetic surveys, expression profiling of coding and non-coding RNAs, SNP and copy number profiling, and functional assays. Analysis of these large, diverse datasets holds the promise of a more comprehensive understanding of the genome and its relation to human disease. Experienced and knowledgeable human review is an essential component of this process, complementing computational approaches. This calls for efficient and intuitive visualization tools able to scale to very large datasets and to flexibly integrate multiple data types, including clinical data. However, the sheer volume and scope of data poses a significant challenge to the development of such tools. To address this challenge we developed the Integrative Genomics Viewer (IGV), a lightweight visualization tool that enables intuitive real-time exploration of diverse, large-scale genomic datasets on standard desktop computers. It supports flexible integration of a wide range of genomic data types including aligned sequence reads, mutations, copy number, RNAi screens, gene expression, methylation, and genomic annotations (Figure S1). The IGV makes use of efficient, multi-resolution file formats to enable real-time exploration of arbitrarily large datasets over all resolution scales, while consuming minimal resources on the client computer (see Supplementary Text). Navigation through a dataset is similar to Google Maps, allowing the user to zoom and pan seamlessly across the genome at any level of detail from whole-genome to base pair (Figure S2). Datasets can be loaded from local or remote sources, including cloud-based resources, enabling investigators to view their own genomic datasets alongside publicly available data from, for example, The Cancer Genome Atlas (TCGA) 1 , 1000 Genomes (www.1000genomes.org/), and ENCODE 2 (www.genome.gov/10005107) projects. In addition, IGV allows collaborators to load and share data locally or remotely over the Web. IGV supports concurrent visualization of diverse data types across hundreds, and up to thousands of samples, and correlation of these integrated datasets with clinical and phenotypic variables. A researcher can define arbitrary sample annotations and associate them with data tracks using a simple tab-delimited file format (see Supplementary Text). These might include, for example, sample identifier (used to link different types of data for the same patient or tissue sample), phenotype, outcome, cluster membership, or any other clinical or experimental label. Annotations are displayed as a heatmap but more importantly are used for grouping, sorting, filtering, and overlaying diverse data types to yield a comprehensive picture of the integrated dataset. This is illustrated in Figure 1, a view of copy number, expression, mutation, and clinical data from 202 glioblastoma samples from the TCGA project in a 3 kb region around the EGFR locus 1, 3 . The investigator first grouped samples by tumor subtype, then by data type (copy number and expression), and finally sorted them by median copy number over the EGFR locus. A shared sample identifier links the copy number and expression tracks, maintaining their relative sort order within the subtypes. Mutation data is overlaid on corresponding copy number and expression tracks, based on shared participant identifier annotations. Several trends in the data stand out, such as a strong correlation between copy number and expression and an overrepresentation of EGFR amplified samples in the Classical subtype. IGV’s scalable architecture makes it well suited for genome-wide exploration of next-generation sequencing (NGS) datasets, including both basic aligned read data as well as derived results, such as read coverage. NGS datasets can approach terabytes in size, so careful management of data is necessary to conserve compute resources and to prevent information overload. IGV varies the displayed level of detail according to resolution scale. At very wide views, such as the whole genome, IGV represents NGS data by a simple coverage plot. Coverage data is often useful for assessing overall quality and diagnosing technical issues in sequencing runs (Figure S3), as well as analysis of ChIP-Seq 4 and RNA-Seq 5 experiments (Figures S4 and S5). As the user zooms below the ~50 kb range, individual aligned reads become visible (Figure 2) and putative SNPs are highlighted as allele counts in the coverage plot. Alignment details for each read are available in popup windows (Figures S6 and S7). Zooming further, individual base mismatches become visible, highlighted by color and intensity according to base call and quality. At this level, the investigator may sort reads by base, quality, strand, sample and other attributes to assess the evidence of a variant. This type of visual inspection can be an efficient and powerful tool for variant call validation, eliminating many false positives and aiding in confirmation of true findings (Figures S6 and S7). Many sequencing protocols produce reads from both ends (“paired ends”) of genomic fragments of known size distribution. IGV uses this information to color-code paired ends if their insert sizes are larger than expected, fall on different chromosomes, or have unexpected pair orientations. Such pairs, when consistent across multiple reads, can be indicative of a genomic rearrangement. When coloring aberrant paired ends, each chromosome is assigned a unique color, so that intra- (same color) and inter- (different color) chromosomal events are readily distinguished (Figures 2 and S8). We note that misalignments, particularly in repeat regions, can also yield unexpected insert sizes, and can be diagnosed with the IGV (Figure S9). There are a number of stand-alone, desktop genome browsers available today 6 including Artemis 7 , EagleView 8 , MapView 9 , Tablet 10 , Savant 11 , Apollo 12 , and the Integrated Genome Browser 13 . Many of them have features that overlap with IGV, particularly for NGS sequence alignment and genome annotation viewing. The Integrated Genome Browser also supports viewing array-based data. See Supplementary Table 1 and Supplementary Text for more detail. IGV focuses on the emerging integrative nature of genomic studies, placing equal emphasis on array-based platforms, such as expression and copy-number arrays, next-generation sequencing, as well as clinical and other sample metadata. Indeed, an important and unique feature of IGV is the ability to view all these different data types together and to use the sample metadata to dynamically group, sort, and filter datasets (Figure 1 above). Another important characteristic of IGV is fast data loading and real-time pan and zoom – at all scales of genome resolution and all dataset sizes, including datasets comprising hundreds of samples. Finally, we have placed great emphasis on the ease of installation and use of IGV, with the goal of making both the viewing and sharing of their data accessible to non-informatics end users. IGV is open source software and freely available at http://www.broadinstitute.org/igv/, including full documentation on use of the software. Supplementary Material 1
                Bookmark

                Author and article information

                Journal
                101573691
                39703
                Cell Rep
                Cell Rep
                Cell reports
                2211-1247
                7 April 2023
                28 March 2023
                28 February 2023
                24 April 2023
                : 42
                : 3
                : 112194
                Affiliations
                [1 ]Department of Pediatric Surgery, Massachusetts General Hospital, Boston, MA, USA
                [2 ]Neurosciences Graduate Program, Stanford University, Stanford, CA, USA
                [3 ]Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA
                [4 ]Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA
                [5 ]Lead contact
                Author notes

                AUTHOR CONTRIBUTIONS

                Conceptualization, R.A.G. and A.M.G.; methodology, R.A.G., A.M.G., K.R., J.A.K., and R.S.; formal analysis, R.A.G. and R.S.; investigation, R.A.G., S.B., K.R., J.L.M., and N.M.P.; resources, A.M.G., R.H., and J.A.K.; data curation, R.A.G. and R.S.; writing – original draft, R.A.G. and A.M.G.; writing – review & editing, R.A.G., R.S., K.R., J.A.K., R.H., N.M.P., J.L.M., and A.M.G.; supervision, A.M.G., R.H., and J.A.K.; project administration, A.M.G. and R.H.; funding acquisition, R.A.G., A.M.G., and J.A.K.

                [* ]Correspondence: agoldstein@ 123456partners.org
                Article
                NIHMS1887281
                10.1016/j.celrep.2023.112194
                10123761
                36857184
                d6400a8c-06ae-4a2f-9677-54d1084bc90d

                This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Categories
                Article

                Cell biology
                Cell biology

                Comments

                Comment on this article